Your browser doesn't support javascript.
loading
Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Erin, Nuray; Tavsan, Esra; Akdeniz, Özlem; Isca, Vera M S; Rijo, Patricia.
Affiliation
  • Erin N; Akdeniz University, Faculty of Medicine, Department of Medical Pharmacology, Antalya, Turkey; Immunopharmacology and Immunooncology Unit, Antalya, Turkey. Electronic address: nerin@akdeniz.edu.tr.
  • Tavsan E; Akdeniz University, Faculty of Medicine, Department of Medical Pharmacology, Antalya, Turkey; Immunopharmacology and Immunooncology Unit, Antalya, Turkey.
  • Akdeniz Ö; Akdeniz University, Faculty of Medicine, Department of Medical Pharmacology, Antalya, Turkey.
  • Isca VMS; CBIOS-Center for Research in Biosciences & Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, 1749-024 Lisboa, Portugal; Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal.
  • Rijo P; CBIOS-Center for Research in Biosciences & Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, 1749-024 Lisboa, Portugal; Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal. Electronic address: pa
Cytokine ; 142: 155498, 2021 06.
Article in En | MEDLINE | ID: mdl-33773907
ABSTRACT
Activation of CXCR2 by chemokines such as CXCL1 and CXCL2 increases aggressiveness of breast cancer, inducing chemoresistance, hence CXCR2 antagonists are in clinical trials. We previously reported that inhibition of CXCR2 increases MIP-2 (CXCL2), which may inhibit anti-tumoral effects of CXCR2 antagonists. This seems to be due to inhibition of protein kinase C (PKC) by CXCR2 antagonist since specific inhibitor of PKC also enhances MIP-2 secretion. We here examined whether CXCR2 inhibitor also increases KC (CXCL1) secretion, ligand for CXCR2 involved in metastasis and PKC activators can prevent increases in chemokine secretion. We used SB 225002, which is a specific CXCR2 antagonist. The effects of PKC activators that have documented anti-tumoral effects and activates multiple isozymes of PKC such as Ingenol-3-angelate (I3A) and bryostatin-1 were examined here. In addition, FR236924, PKCε selective and 7α-acetoxy-6ß-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), PKCδ selective activators were also tested. The effects of activators were determined using brain metastatic (4TBM) and heart metastatic (4THM) subset of 4T1 breast carcinoma cells because these aggressive carcinoma cells with cancer stem cell features secrete high levels of KC and MIP-2. Inhibition of CXCR-2 activity increased KC (CXCL1) secretion. PKC activators prevented SB225002-induced increases in KC and MIP-2 secretion. Different activators/modulators induce differential changes in basal and SB225002-induced chemokine secretion as well as cell proliferation and the activators that act on PKCδ and/or PKCε such as bryostatin 1, FR236924 and Roy-Bz are the most effective. These activators alone also decrease cell proliferation or chemokine secretion or both. Given the role of KC and MIP-2 in drug resistance including chemotherapeutics, activators of PKCε and PKCδ may prevent emerging of resistance to CXCR2 inhibitors as well as other chemotherapeutics.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mammary Neoplasms, Animal / Chemokines / Enzyme Activators / Receptors, Interleukin-8B / Protein Kinase C-delta / Protein Kinase C-epsilon Limits: Animals Language: En Journal: Cytokine Journal subject: ALERGIA E IMUNOLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mammary Neoplasms, Animal / Chemokines / Enzyme Activators / Receptors, Interleukin-8B / Protein Kinase C-delta / Protein Kinase C-epsilon Limits: Animals Language: En Journal: Cytokine Journal subject: ALERGIA E IMUNOLOGIA Year: 2021 Document type: Article